Yes but it's really only an issue if there was sufficient market...

Yes but it's really only an issue if there was sufficient market to secure profitability. So far Avita has struggled despite the huge margins on an overpriced plastic kit with some trypsin and a couple of syringes so nobody would be interested. Any generic competitor would have a far easier path since they could likely demonstrate sufficient similarly to an already approved product (Recell). So yes once the patent expires then a company in China or India could sell competing generic devices for a fraction of the price with minimal effort.